BSPED Logo  (An Orchidometer)  - Click this image to return to the home page BSPED - Helping support children with endocrinological disorders and diabetes  mellitus
spacer
spacer
| Home | Professionals |   Patients | Members | About | Contact | Sitemap  
spacer
spacer
 Patients Home |   Nick's Notes | Serono/CGF Booklets | Resources  
spacer
spacer
 Nick's Notes spacer
bullet: Achondroplasia
bullet: Congenital Adrenal Hyperplasia (21 hydroxylase)
bullet: Congenital Adrenal Hyperplasia (11 hydroxylase)
bullet: Congenital Adrenal Hyperplasia - treatment in pregnancy
bullet: Complete Androgen Insensitivity Syndrome (CAIS)
bullet: Congenital Hypothyroidism
bullet: Coeliac Disease
bullet: Delayed Puberty
bullet: Diabetes Insipidus
bullet: Graves' Disease (Thyrotoxicosis)
bullet: Growing Pains
bullet: Gynaecomastia
bullet: Hypopituitarism
bullet: Hypothyroidism (Acquired)
bullet: Klinefelter's Syndrome
bullet: Labial Adhesions
bullet: Marfan's Syndrome
bullet: Overweight
bullet: Partial Androgen Insensitivity Syndrome (PAIS)
bullet: Precocious Puberty
bullet: Steroid Replacement
bullet: Steroid Treatment
bullet: Tall Stature
bullet: Turner's Syndrome

spacer
home > patients > Nick's Notes  
spacer

 Nick's Notes

spacer

ACHONDROPLASIA

Achondroplasia is a genetic condition which primarily involves the skeleton and so restricts growth. It is rare, affecting only about 1 in 20,000 people.

Cause:

Each human cell contains 46 chromosomes in 23 pairs, one of each pair inherited from the mother and one from the father. Each chromosome carries many genes like a row of pearls. Achrondroplasia is caused by a fault in a single dominant gene, this implies that the disease is expressed although only one of a pair of genes is affected. Males and females are equally likely to be affected and have a 50% chance of passing the abnormal gene, and so the condition, on to children of either sex. However, in achondroplasia about three-quarters of affected people represent new mutations, a situation in which the abnormality of the gene arises spontaneously before birth and is not inherited from either parent. Unfortunately, the gene can then be passed to later generations. In 1994 it was found that the gene for achondroplasia lies on the short arm (each gene has a short and a long arm) of chromosome 4 at the site of the gene for a growth factor receptor (FGFR3), a protein in the outer wall of cells in growing bone which receive the message to divide. Nearly all affected people studied so far have had identical mutations in this gene; this is very unusual and indicates that this is the gene most highly susceptible to mutation in the human. The mutation is easily detected so for couples at risk (because one parent is affected) prenatal diagnosis from chorionic villus sampling (removal of a sample from the placenta in early pregnancy) is now possible.

Physical features:

The physical and X-ray features of achondroplasia are remarkably constant. Affected babies are short at birth and grow slowly throughout childhood, the average final height for women is 126cm (4ft 2in) and for men is 131cm (4ft 4in). The limbs are relatively shorter than the trunk with the the upper arm and the thigh especially shortened The head is usually large with prominence of the forehead and a flat nasal bridge. The fingers and toes are short and the hands and feet small and wide. The spine seldom has a sideways curve but may have an exaggerated lumbar curve. Children often show some early hypotonia (floppiness) of the limbs with delayed motor development but this usually improves and disappears in childhood. There may be dental problems from malocclusion of the teeth. In childhood recurrent episodes of ear infection and glue ear are common which may lead to temporary loss of hearing and interference with speech development. Achondroplasia may be complicated by hydrocephalus, an excess of fluid within the head resulting from obstruction of the flow of cerebrospinal fluid or by compression of the nerves leaving the spinal cord.

Treatment:

There is no specific treatment but it is desirable to monitor the progress of affected children to offer support and to detect early the occurrence of any complications. Most children cope remarkably well with the problems arising from their short stature and most schools are helpful. Attempts to increase final height with growth hormone treatment have not been successful but in recent years surgical bone-lengthening procedures have been developed in several centres. These require major surgery, which is generally done in at least two operations, and the wearing of heavy and uncomfortable expandable bone braces for many months, typically about 18 months. If all goes well a really significant gain in height can be achieved, about 10-12in (25-30cm). Clearly such surgery is a major undertaking for both the child and the family and the decision to go ahead has to be most carefully considered.

Outlook:

Most people with achondroplasia cope extraordinarily well with the physical difficulties and lead successful and fulfilled lives. Many have distinguished themselves in various fields. The Restricted Growth Association (103 St Thomas Avenue, West Town, Hayling Island, Hants PO11 OEU) is an important source of help on this and other related conditions. NDB

spacer
 See also...
bullet: Serono/CGF Booklets
bullet: Resources
spacer
 Disclaimer |  Privacy spacer